<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039672</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0248</org_study_id>
    <nct_id>NCT04039672</nct_id>
  </id_info>
  <brief_title>Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma</brief_title>
  <acronym>MELANOPREDICT</acronym>
  <official_title>Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAF Inhibitors/MEK Inhibitors (BRAFi/MEKi) in BRAF Mutated Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional mono-centric study in patients with BRAF mutated metastatic&#xD;
      melanoma treated with BRAF/MEK inhibitors. The aim of the study is to test the grafting of&#xD;
      patient tumoral cells in avian embryo and develop a predictive in vivo model for patient&#xD;
      treatment response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grafted avian embryo development</measure>
    <time_frame>2 days post graft</time_frame>
    <description>Number of grafted embryo which develop tumor measurable by 3D microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grafted avian embryo viability</measure>
    <time_frame>2 days post graft</time_frame>
    <description>Survival rate of grafted embryo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BRAFi/MEKi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Survival rate in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRAFi maximum toxic effect dose in avian embryon</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Survival rate in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEKi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>weight of avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRAFi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Height of avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEKi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Height of avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRAFi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Presence of cardiac malformation in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEKi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Presence of cardiac malformation in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRAFi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Presence of craniofacial malformation in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEKi maximum toxic effect dose in avian embryo</measure>
    <time_frame>3 months post treatment administration</time_frame>
    <description>Presence of craniofacial malformation in avian embryo after treatment injections in different concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient treatment response</measure>
    <time_frame>3 months post inclusion</time_frame>
    <description>RECIST 1.1 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo treatment response (tumor)</measure>
    <time_frame>2 days post graft</time_frame>
    <description>Embryo tumor volume obtained by confocal microscopy before treatment administration compared with tumor volume of non-treated embryo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo treatment response (metastasis)</measure>
    <time_frame>2 days post graft</time_frame>
    <description>Metastasis appearance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin biopsy before BRAFi/MEKi treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>5mm skin metastasis or primary melanoma biopsy</description>
    <arm_group_label>Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 18 years&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Patient with BRAF V600 mutated metastatic or unresectable melanoma histologically&#xD;
             confirmed&#xD;
&#xD;
          -  BRAFi/MEKi treatment indication&#xD;
&#xD;
          -  Patient with skin tumor (excluded face and skinfold) available for biopsy&#xD;
&#xD;
          -  Measurable disease as defined by RECIST v1.1 criteria&#xD;
&#xD;
          -  Patient affiliated to or a beneficiary of a social security category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular melanoma&#xD;
&#xD;
          -  Medical, psychiatric, cognitive or other conditions that may compromise the patient's&#xD;
             ability to understand the patient information, give informed consent, comply with the&#xD;
             study protocol or complete the study&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Patients protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stéphane DALLE, MD, Prof.</last_name>
    <phone>478861679</phone>
    <phone_ext>+33</phone_ext>
    <email>stephane.dalle@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Dermatologie, Centre hospitalier Lyon Sud, HCL</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane DALLE, MD, Prof.</last_name>
      <phone>478861679</phone>
      <phone_ext>+33</phone_ext>
      <email>stephane.dalle@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane DALLE, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Avian embryo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

